Clinical Trial Update: Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating intravitreal aflibercept in neovascular age-related macular degeneration with limited response to ranibizumab.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Aflibercept (Aflibercept)
• Ranibizumab (ranibizumab)

Snippet

Sponsor: Vista Klinik | Conditions: Neovascular Age-related Macular Degeneration | Phase 4 | Status: COMPLETED